The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Mass spectrometry kinetics of monoclonal protein clearance in multiple myeloma
Noemi Puig, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses preliminary findings on the kinetics of monoclonal protein clearance measured by mass spectrometry in patients with multiple myeloma who have achieved complete response. She highlights differences in clearance kinetics between IgG and IgA monoclonal proteins and the potential for persistent mass spectrometry positivity to reflect delayed protein clearance rather than residual disease, while emphasizing the need for longer follow-up and additional samples. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we have presented these results in the form of a poster, and basically what we wanted to address, I have to say that these are preliminary results, but we wanted to address what is the kinetics of the clearance of the monoclonal protein when assessed by mass spectrometry in patients with myeloma. And as I said, they are preliminary results, but basically we have more or less confirmed what we knew...
So we have presented these results in the form of a poster, and basically what we wanted to address, I have to say that these are preliminary results, but we wanted to address what is the kinetics of the clearance of the monoclonal protein when assessed by mass spectrometry in patients with myeloma. And as I said, they are preliminary results, but basically we have more or less confirmed what we knew. So the fact that to clear IgG takes longer as compared to clear the monoclonal protein from patients with IgA isotype. And so what we want to address better is how to implement this knowledge in the interpretation of the results of mass spectrometry. So the background of this, or the reason for this, is that you can get a positive result using mass spectrometry that can be due just to the lack of clearance of the monoclonal protein, but that is not associated with true disease in the bone marrow of the patient. And with this study, we wanted to address that. But as I said, we have confirmed previous results, but I have to say that these results are preliminary. We have to follow the patients longer and we have to include more samples to extract some definite conclusions regarding this.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
